心血管医学

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

   Rochester, Minn.

   The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.

2. A Study of Sexual Dysfunction in Patients with Hypertrophic Obstructive Cardiomyopathy Undergoing Septal Myectomy

   Rochester, Minn.

   The purpose of this study is to determine how many patients suffer from sexual function problems and ascertain if they are improved or modified by cardiac surgical intervention.

3. Hospital Diuretic Therapy and Associated Risk of Heart Failure in Treating Fluid Volume Overload

   Rochester, Minn.

   The objective of this proposal is to assess blood-plasma volume (TBV-PV) status quantitatively in patients with DHF admitted to hospital for volume management, and to determine how effective standard diuretic therapy is in achieving euvolemia and the impact of their quantitated volume status at the time of hospital discharge on heart failure related morality and re-hospitalizations. Thus, to determine if quantitative blood volume analysis could potentially serve as an effective tool to guide more effective in-hospital diuretic therapy to achieve better outcomes in patients hospitalized with clinically identified volume overload.

4. A Repository of Atria Tissue for the Investigation of Atrial Pathophysiology in Patients with Atrial Fibrillation

   Rochester, Minn.

   The purpose of this study is to collect surgically removed atrial tissue for genetic, pathologic, metabolic, and molecular studies in patients with or without a history of atrial fibrillation.

5. A Study to Evaluate Perceptions of Midline Sternotomy Scar in Children and Young Adults

   Rochester, Minn.

   The purpose of this study is to evaluate how children and young adults perceive their midline sternotomy scars (in terms of appearance, associated symptoms, consciousness, satisfaction with appearance/symptoms, and impact on quality of life)? 

6. A Study to Establish a Registry for the Pulmonary Hypertension Association

   Jacksonville, Fla.

   The objectives of this study are to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes); determine the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches; understand risk factors for outcomes and regional/center differences; and facilitate funded clinical trials of new therapies and collaboration with the PAH community at large, including providers, patients, and their caregivers.

7. Study to Determine the Accuracy of a New Venous Air Plethysmograph in People with Normal, Incompetent, and Obstructed Venous Hemodynamics.

   Rochester, Minn.

   The purpose of this study is to determine the accuracy (sensitivity, specificity, negative predictive value, positive predictive value) of a new venous air plethysmograph in people with normal, incompetent, and obstructed venous hemodynamics.

8. Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

    

9. A Study to Evaluate DDP3 as a Predictor of Cardiogenic Shock in Patients Presenting with Cardiac Symptoms

   Rochester, Minn.

   The purpose of this study is to evaluate whether DDP3 identifies patients at early risk of cardiogenic shock presenting with STEMI in order to benefit from more aggressive cardiology scrutiny.

    

    

10. A Study to Assess the Current FDA-approved AliveCor Kardia Device to Measure the QT/QTc in Patients Presenting to the Genetic Heart Rhythm Clinic

    Rochester, Minn.

    The purpose of this study is to assess the feasibility of using the current FDA-approved AliveCor Kardia device and their AliveCor Tripod device (FDA Approval pending) to measure the QT/QTc in patients presenting to the Genetic Heart Rhythm Clinic.